Cargando…

Aprotinin Inhibits SARS-CoV-2 Replication

Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the current coronavirus disease 19 (COVID-19) pandemic. Protease inhibitors are under consideration as virus entry inhibitors that prevent the cleavage of the coronavirus spike (S) protein by cellular proteases. Herein, we showed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bojkova, Denisa, Bechtel, Marco, McLaughlin, Katie-May, McGreig, Jake E., Klann, Kevin, Bellinghausen, Carla, Rohde, Gernot, Jonigk, Danny, Braubach, Peter, Ciesek, Sandra, Münch, Christian, Wass, Mark N., Michaelis, Martin, Cinatl, Jindrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7692688/ https://www.ncbi.nlm.nih.gov/pubmed/33143316 http://dx.doi.org/10.3390/cells9112377

Ejemplares similares

COVID-19-Related Coagulopathy—Is Transferrin a Missing Link?
por: McLaughlin, Katie-May, et al.
Publicado: (2020)

Differentially conserved amino acid positions may reflect differences in SARS-CoV-2 and SARS-CoV behaviour
por: Bojkova, Denisa, et al.
Publicado: (2021)

Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication
por: Klann, Kevin, et al.
Publicado: (2020)

SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment
por: Bojkova, Denisa, et al.
Publicado: (2022)

Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates
por: Bojkova, Denisa, et al.
Publicado: (2022)

A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis
por: McLaughlin, Katie-May, et al.
Publicado: (2021)

Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants
por: Bojkova, Denisa, et al.
Publicado: (2022)

SARS-CoV-2 Variants Show Different Host Cell Proteome Profiles With Delayed Immune Response Activation in Omicron-Infected Cells
por: Metzler, Melinda, et al.
Publicado: (2023)

Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy
por: Bojkova, Denisa, et al.
Publicado: (2021)

Omeprazole Increases the Efficacy of Acyclovir Against Herpes Simplex Virus Type 1 and 2
por: Michaelis, Martin, et al.
Publicado: (2019)

Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARS-CoV-2-Infected Cells
por: Schäfer, Richard, et al.
Publicado: (2020)

Pseudomonas aeruginosa Affects Airway Epithelial Response and Barrier Function During Rhinovirus Infection
por: Endres, Adrian, et al.
Publicado: (2022)

Evaluation of stability and inactivation methods of SARS-CoV-2 in context of laboratory settings
por: Widera, Marek, et al.
Publicado: (2021)

3DLigandSite: structure-based prediction of protein–ligand binding sites
por: McGreig, Jake E, et al.
Publicado: (2022)

Drug-adapted cancer cell lines as preclinical models of acquired resistance
por: Michaelis, Martin, et al.
Publicado: (2019)

Lack of antiviral activity of darunavir against SARS-CoV-2
por: De Meyer, Sandra, et al.
Publicado: (2020)

Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin
por: Dilruba, Shahana, et al.
Publicado: (2020)

Optimized qRT-PCR Approach for the Detection of Intra- and Extra-Cellular SARS-CoV-2 RNAs
por: Toptan, Tuna, et al.
Publicado: (2020)

SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine
por: Rothenburger, Tamara, et al.
Publicado: (2020)

Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line
por: Saafan, Hisham, et al.
Publicado: (2021)

Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells
por: Rothenburger, Tamara, et al.
Publicado: (2021)

Characterization of ACE Inhibitors and AT(1)R Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model
por: Reus, Philipp, et al.
Publicado: (2021)

Anti-tumour Activity of Aprotinin
por: Latner, A. L., et al.
Publicado: (1974)

Antifibrinolytic Agents: Aprotinin, and Desmopressin
por: Bajaj, Pramila
Publicado: (2009)

Identification of an aprotinin antiviral domain
por: Pellegrini, Antonio, et al.
Publicado: (1994)

A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection
por: Ellinger, Bernhard, et al.
Publicado: (2021)

In vitro activity of itraconazole against SARS‐CoV‐2
por: Van Damme, Ellen, et al.
Publicado: (2021)

Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform
por: Bojkova, Denisa, et al.
Publicado: (2023)

Aprotinin—Drug against Respiratory Diseases
por: Ivachtchenko, Alexandre V., et al.
Publicado: (2023)

Incorporation of doxorubicin in different polymer nanoparticles and their anticancer activity
por: Pieper, Sebastian, et al.
Publicado: (2019)

Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells
por: Onafuye, Hannah, et al.
Publicado: (2019)

A disheartening story: Aprotinin in cardiac surgery
por: Lien, Marcus, et al.
Publicado: (2006)

Aprotinin and growth of Walker 256 carcinosarcoma in the rat.
por: Thomson, A. W., et al.
Publicado: (1977)

Silver N-heterocyclic carbene complexes are potent uncompetitive inhibitors of the papain-like protease with antiviral activity against SARS-CoV-2
por: Gil-Moles, Maria, et al.
Publicado: (2023)

USP22 controls type III interferon signaling and SARS-CoV-2 infection through activation of STING
por: Karlowitz, Rebekka, et al.
Publicado: (2022)

Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection
por: de Bruin, Natasja, et al.
Publicado: (2022)

Effect of aprotinin on immunological resistance in tumour-bearing animals.
por: Latner, A. L., et al.
Publicado: (1976)

Institutional response to FDA warning on aprotinin and impact on outcomes
por: Swaminathan, M, et al.
Publicado: (2009)

Comparison of Tranexamic Acid with Aprotinin in pediatric cardiac surgery
por: Chauhan, Sandeep
Publicado: (2015)

The druggable genome: Twenty years later
por: Radoux, Chris J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jt3fbvg9koeg9apqvmqvslhg9e